Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 9/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617212 | 0.87 | MEN1 (0.49) | PDCD1LG2CD274L3MBTL1MAPTKMT2A | |
| SCHEMBL20719190 | 0.80 | PDCD1LG2 (0.41) | PDCD1LG2CD274L3MBTL1MAPTKMT2A | |
| SCHEMBL12478386 | 0.80 | PDCD1LG2 (0.42) | PDCD1LG2CD274L3MBTL1MAPTKMT2A | |
| SCHEMBL19237081 | 0.74 | CD274 (0.46) | PDCD1LG2CD274L3MBTL1MAPTKMT2A | |
| SCHEMBL31523455 | 0.74 | CD274 (0.46) | PDCD1LG2CD274L3MBTL1MAPTKMT2A | |
| SCHEMBL20719167 | 0.73 | CD274 (0.40) | PDCD1LG2CD274L3MBTL1MAPTKMT2A | |
| SCHEMBL23066276 | 0.73 | MMP8 (0.42) | L3MBTL1MAPTKMT2ATDP1MEN1 | |
| SCHEMBL30492990 | 0.73 | MMP8 (0.42) | L3MBTL1MAPTKMT2ATDP1MEN1 | |
| SCHEMBL20719115 | 0.72 | RAB9A (0.41) | L3MBTL1MAPTGAACYP1A2CYP3A4 | |
| SCHEMBL16626056 | 0.72 | L3MBTL1 (0.41) | L3MBTL1MAPTKMT2AGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3055300-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | Pfizer Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2015052610-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052610-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PTGER3, PTGES3, PTGER2 | PDCD1LG2 3493/4885CD274 3466/4885L3MBTL1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.